Pacira BioSciences (PCRX) Change in Accured Expenses (2010 - 2026)

Pacira BioSciences' Change in Accured Expenses history runs 17 years deep, the most recent figure standing at $3.3 million for Q1 2026.

• In Q1 2026, Change in Accured Expenses fell 30.07% year-over-year to $3.3 million; the TTM figure through Mar 2026 stood at $5.4 million (down 72.68% YoY), while the FY2025 annual figure was $6.9 million, down 52.52% from the prior year.
• Change in Accured Expenses was $3.3 million for Q1 2026 at Pacira BioSciences, up from $1.8 million in the prior quarter.
• In the past five years, Change in Accured Expenses ranged from a high of $15.6 million in Q4 2024 to a low of -$24.0 million in Q3 2022.
• Historically, Change in Accured Expenses has averaged -$993352.9 across 5 years, with a median of $421000.0 in 2023.
• Biggest YoY gain for Change in Accured Expenses was 8630.97% in 2022; the steepest drop was 2273.51% in 2022.
• A 5-year view of Change in Accured Expenses shows it stood at $3.7 million in 2022, then sank by 684.53% to -$21.6 million in 2023, then surged by 172.21% to $15.6 million in 2024, then tumbled by 88.65% to $1.8 million in 2025, then jumped by 85.34% to $3.3 million in 2026.
• The last three Change in Accured Expenses figures came in at $3.3 million (Q1 2026), $1.8 million (Q4 2025), and -$5.8 million (Q3 2025), per Business Quant data.